Stephanie L. Graff, MD
The rise of CDK4/6 inhibitors, PARP inhibitors, and other targeted therapies has allowed for patients with metastatic breast cancer to be treated on an individualized basis, explained Stephanie L. Graff, MD. Nevertheless, much work remains in the coming years for breast oncologists.
State of the Science Summit™ on A Summer of Progress: Updates from ASCO 2018, Graff discussed the current and evolving landscape of breast oncology and what this means for patients.
OncLive: Please provide background on your presentation on metastatic breast cancer.
: One highlight of my presentation was the role of CDK4/6 inhibitors. They are clearly now a mainstay in the treatment of patients with HR-positive metastatic breast cancer. At the 2018 ASCO Annual Meeting, we saw updates looking at both frontline and second-line CDK4/6 inhibitors for a premenopausal population. Interestingly, there was an FDA-pooled analysis from Dr Jennifer Gao that took women with metastatic ER-positive breast cancer across all the CDK4/6 inhibitors and looked to see if all the patient populations equally benefitted. The answer was a resounding “Yes.”
We also have dipped our toes into the field of PARP inhibitors, as well as the TOPACIO study, which looked at PARP inhibitors paired with immunotherapy. We saw a really good response there.
Along with CDK4/6 inhibitors, there were some exciting data presented about abemaciclib. Could you speak to that?
For the CDK4/6 inhibitors, we saw that there is clear evidence that they’re effective in premenopausal women. We now have premenopausal data for the big 3: ribociclib, abemaciclib, and palbociclib. All of those agents have been used in combination with aromatase inhibitors plus a medicine for ovarian suppression. The fact that premenopausal women are getting the same hazard ratio and same ORR tells us that this is still a very positive, meaningful treatment. This is definitely something I’m doing in my clinic.
... to read the full story